Learn about emerging treatments for advanced lymphoma. We’ve got it covered, from new FDA approvals to emerging approaches in targeted therapy, CAR T-cell therapy, other forms of immunotherapy, and more.

  • October 16, 2020 

    Lymphoblastic Lymphoma—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2019 comprehensive presentation of lymphoblastic (precursor B-cell and T-cell) lymphoma emphasizes lymph node-predominant involvement in this blood-lymph node diaspora. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020 

    Hodgkin Lymphoma—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to a potentially curable form of lymphoma is richly detailed and specific for all types and stages of Hodgkin lymphoma. (Free registration required, written with a physician audience in mind.)

    .

  • October 8, 2020 

    First Approval of Second-Line Therapy for DLBCLBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .

  • December 2, 2019 

    Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICMLBookmark

    George Lundberg, MD

    Continuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes: 

    Recent research findings can change practices for B-cell malignancies.

    Go to educational module at Clinical Care Options (requires free registration).

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    FDA Approves Acalabrutinib for CLL/SLL as Part of Project OrbisBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
Precision oncology is very complicated and changes every day. The scientists of Cancer Commons provide rapid, compassionate, scientifically sound information about best options, a remarkable free service.

Razelle Kurzrock, MD
U.C. San Diego, CureMatch, Inc.

It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.

Keith Flaherty, MD
Cancer Commons Advisor

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • October 14, 2019 

    Pediatric Palliative Care: A Specialty Comes of Age

    Sarah Friebert, MD

    For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is… Read more »

  • February 11, 2020 

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 7, 2019 

    Emphasizing Oncogeriatrics

    With: Nicolò Matteo Luca Battisti, MD

    A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International… Read more »

  • December 3, 2018 

    Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer

    With: Val Jones, MD

    A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical… Read more »

  • September 14, 2018 

    Huge Progress in Palliative Care

    With: Diane E. Meier, MD, FACP

    A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY;… Read more »

  • July 23, 2018 

    Cancer Pain and the Opioid Epidemic

    George Lundberg, MD

    A Q&A with Kevin Sevarino, MD, PhD, President-elect of the American Academy of Addiction Psychiatry and Consulting Psychiatrist at Gaylord Hospital in Wallingford, CT Q: Opioid abuse, addiction, and overdose… Read more »

    • Show More

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories.

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.